Navigation Links
Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
Date:5/14/2015

CAMBRIDGE, Mass., May 14, 2015 /PRNewswire/ -- Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology annual meeting, held from May 29 to June 2, 2015, in Chicago, IL.

Data to be highlighted at the meeting show the potential of BBI608—an orally-administered investigational agent that targets STAT3, leading to inhibition of the critical genes for maintaining cancer stemness—for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including gastric and colorectal. The study protocol from the BRIGHTER study, the phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibitors, will also be showcased.

Additional data featuring BBI503—an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases—showed encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer.

Also, findings from a publication-only abstract will be available:

  • Abstract #e15089: A phase 1 study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer
    • Kohei Shitara, MD, National Cancer Center Hospital East

"We look forward to sharing these encouraging findings of first-in-class compounds BBI608 and BBI503 at this year's ASCO annual meeting," said Chiang J. Li, M.D. FACP, the President, CEO and Chief Medical Officer of Boston Biomedical, and the Head of Global Oncology for Sumitomo Dainippon Pharma Group. "We are pleased to see the progress to date and are planning for the continued evaluation of these compounds that may ultimately improve patient care and shift the treatment continuum."

Poster presentations include:

  • Monday, June 1 from 8:00 a.m. – 11:30 a.m. (Gastrointestinal (Colorectal) Cancer), S Hall A
    • Abstract #3615, Poster #108: Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer
      • Derek J. Jonker, MD, FRCPC, The Ottawa Hospital Cancer Centre
    • Abstract #3616, Poster #109: A phase 1b study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC)
      • Joleen Marie Hubbard, MD, Mayo Clinic
    • Abstract #3617, Poster #110: A phase 1b/2 study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy
      • Kristen Keon Ciombor, MD, Ohio State University Wexner Medical Center
  • Monday, June 1 from 8:00 a.m. – 11:30 a.m. (Gastrointestinal (Noncolorectal) Cancer), S Hall A
    • Abstract #4069, Poster #179: A phase 1b/2 study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma
      • Carlos Becerra, MD, Texas Oncology-Baylor Sammons Cancer Center
    • Abstract #TPS4139, Poster #247a: The BRIGHTER trial: A phase 3 randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma
      • Manish A. Shah, MD, Weill Cornell Medical College

About Boston Biomedical

Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November 2006 and is wholly owned by Sumitomo Dainippon Pharma Co., Ltd. Boston Biomedical's mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stem cell pathways. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the United States, including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute (NCI) cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the "Company To Watch" award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.

Additional information about the company and its product pipeline can be found at www.bostonbiomedical.com.

Disclaimer Regarding Forward-Looking Statements

The forward-looking statements in this document are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Logo - http://photos.prnewswire.com/prnh/20150514/216131LOGO

CONTACT:  For general inquiries, Boston Biomedical, 617-674-6800, or for media inquiries, Bob Josefsberg, CHAMBERLAIN PR, 212-849-9477, bob.josefsberg@inventivhealth.com


'/>"/>
SOURCE Boston Biomedical Pharma, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Completes $1.85 Billion Senior Notes Offering
2. Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2015
3. Boston Scientific Prices $1.85 Billion Of Senior Notes
4. Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day
5. Boston Scientific Collaborates With MedAxiom And TogetherMD To Bring Value Based Solutions To Healthcare Systems
6. Boston Scientific Announces Results for First Quarter 2015
7. Boston Scientific Announces Strategic Collaboration With Brainlab AG
8. Boston Scientific To Participate In The Bank Of America Merrill Lynch 2015 Healthcare Conference
9. Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference
10. LabStyle Innovations to Deliver Poster Presentation at American Diabetes Associations 75th Scientific Sessions on June 5-9, 2015 in Boston
11. Boston Scientific Signs Strategic Alliance With Frankenman Medical Equipment Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... September 01, 2020 , ... ... of Cosmetics and Laser Surgery at the University of Rochester Medical Center, in ... at SkinCare Physicians in Boston, with clinical faculty from the Harvard and Yale ...
(Date:9/1/2020)... ... September 01, 2020 , ... September is National Ovarian Cancer Awareness Month. ... any other cancer of the female reproductive system. The American Cancer Society estimates ... 14,000 women will die from this disease. Throughout the month of September, Women’s ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... and advisory guide, has named Cloudticity a Gold winner in the 15th Annual ... and peer recogniti o ns from Network Products Guide honoring achievements ...
Breaking Medicine Technology:
(Date:9/3/2020)... ... , ... International Dark-Sky Association (IDA) recently bestowed the prestigious ... advanced LED wireless dimming controller, along with the previously IDA approved Dimulator, are ... light pollution. Leo Smith, the Northeast Regional Director for IDA says “We are ...
(Date:9/1/2020)... , ... September 01, 2020 , ... Feeding Matters ... for children with Pediatric Feeding Disorder (PFD), is pleased to announce that the U.S. ... stand-alone diagnostic code (R code) in the next edition of the U.S. International ...
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma Research Foundation ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Blood Cancer Awareness Month (BCAM) and its international Light it Red for ...
(Date:8/31/2020)... ... August 31, 2020 , ... Genesis Chiropractic Software and ... the launch of its integrated, HIPAA compliant, telehealth solution, available to US-based clients ... under 90 seconds. , According to the U.S. Department of Health & ...
(Date:8/31/2020)... ... , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis , At this very ... of panic, experiencing deep anxiety, immense stress, and right now are needing serious relief from ... people on the planet are experiencing a great degree of emotional discomfort, be it fear ...
Breaking Medicine News(10 mins):